Why Replimune Group (REPL) Is Up 15.5% After Key FDA Panel Backing For RP1 Data - And What's Next

Replimune’s Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, ‘High Conviction’ For Approval

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff?

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line

REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’

Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)